Trials / Completed
CompletedNCT05086289
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3526318 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2022-06-17
- Completion
- 2022-06-17
- First posted
- 2021-10-20
- Last updated
- 2023-10-05
- Results posted
- 2023-10-05
Locations
31 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05086289. Inclusion in this directory is not an endorsement.